Tiziana Life Sciences (NASDAQ:TLSA) announced that the final patient has completed the final visit in its Phase 2a INFORM-MS clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS).
Sunrun (NASDAQ:RUN) and Tesla (NASDAQ:TSLA) announced that more than 140,000 residential batteries supplied over 580 megawatts of peak power to California’s electricity grid during an extreme heat event on September 9, 2026.
CAE (NYSE:CAE) announced that it has been awarded a competitive recompete contract valued at approximately $300 million by the U.S. Air Force to continue providing C-130H aircrew training services through December 2035.
NewAmsterdam Pharma (NASDAQ:NAMS) and partner Menarini Group announced that the European Commission has granted marketing authorization for Ubeslo® (10 mg obicetrapib monotherapy) and Evlarco® (10 mg obicetrapib plus 10 mg ezetimibe).
Microchip Technology (NASDAQ:MCHP) announced the completion of its acquisition of Hailo Technologies, a provider of accelerated edge AI processors, vision processors, robotics processors and AI software technologies.
Anixa Biosciences (NASDAQ:ANIX) announced that it received its first Australian composition-of-matter patent for its breast cancer vaccine technology.
BlackLine (NASDAQ:BL) announced the acquisition of NetNow, an AI-enabled B2B customer onboarding and credit risk management platform designed to improve financial operations.
National CineMedia (NASDAQ:NCMI) announced the completion of its previously announced acquisition of Captivate Holdings for an enterprise value of $275 million.
Nuvini Group (NASDAQ:NVNI) reported improved financial performance for the first half of 2026, with operating income reaching R$19.6 million compared with an operating loss of R$32.0 million in the same period last year.
Johnson & Johnson (NYSE:JNJ) announced positive topline results from a pivotal Phase 3 trial evaluating CAPLYTA® (lumateperone) 42 mg once daily for the treatment of acute manic episodes in adults with bipolar I disorder.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
